The FDA is currently reviewing a New Drug Application for vadadustat in this patient population, and a Prescription Drug User Fee Act date has been set for March 29, 2022.
ASN Kidney Week - American Society of Nephrology Kidney Week
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Advertisement
Jung-Im Shin, MD, PhD, assistant professor at Johns Hopkins University Bloomberg School of Public Health, discusses her presentation at American Society of Nephrology’s Kidney Week 2021 on the known and previously established risks associated with rosuvastatin use.
Galindo gave a general overview of his session and explained the new standards of care for chronic kidney disease which he has felt made a great impact on the field.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5